Kevin C. Tang
Chairman & CEOMr. Kevin C. Tang is Chair of the Board & Chief Executive Officer of Tang Capital Acquisition Corp. from August 14, 2026. Mr. Tang is Chief Executive Officer of Aurinia Pharmaceuticals Inc. from March 2026 and serves as its Chairman since 2024. Mr. Tang was Independent Director of Aurinia Pharmaceuticals Inc. from September 12, 2024 to March 2026 & was its Independent Chairman to March 2026. He is Chief Executive Officer and Director of Elevation Oncology, Inc since July 23, 2025. Mr. Tang serves as Director at Tetraphase Pharmaceuticals, Inc. since July 28, 2020. He has been the Chairman and Chief Executive Officer at Odonate Therapeutics, Inc. since 2013. He served as the Chairman of Heron Therapeutics, Inc. since July 30, 2012 until August 4, 2020. He served as an Independent Director of Heron Therapeutics, Inc. since February 2009 until August 4, 2020. He had been the Chairman of La Jolla Pharmaceutical Company since August 2014 until August 22, 2022. Mr. Tang has experience evaluating, creating and building biotechnology companies that are focused on developing treatments for life-threatening and debilitating diseases and conditions. Mr. Tang serves as the President, Chief Financial Officer, Treasurer and Secretary at Solana Therapeutics, Inc. He founded Tang Capital Management, LLC in August 2002 and has been its Managing Director since August 2002 and serves as its President. He held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm from September 1993 to July 2001, most recently serving as Managing Director and Head of the Life Sciences research group. He served as the Chairman of Penwest Pharmaceuticals Co. since 2009 until September 20, 2010 and also served as its Director from June 2009 to September 20, 2010. He serves as a Director at Solana Therapeutics, Inc. He was a Director of Ardea Biosciences, Inc. since May 2003 until its acquisition by AstraZeneca PLC in 2012, which he co-founded in 2006. He served as a Director of CoreLab Partners, Inc. (a/k/a Radpharm, Inc.) since March 1, 2006. He served as a Director of Aclara Biosciences Inc. since November 2002, Ambit Biosciences Corporation and RXi Pharmaceuticals Corporation. He served as a Director of Senomyx Inc. He served as a Director of Intrabiotics Pharmaceuticals Inc. since May 2003. Since 2014, Mr. Tang served as a Director of La Jolla Pharmaceutical Company until August 22, 2022. He was a Director of numerous biotechnology companies and was a Manager of funds specializing in the area of life sciences. He served as a Director of Trimeris Inc. from August 2001 to December 2008. He received his B.S. degree in Psychology from Duke University.
Positions
- Company NameAurinia Pharmaceuticals Inc.Stock CodeAUPHPositionChairman & CEOColleagues
- SPStephen P. RobertsonChief Legal Officer, Corporate Secretary & Chief Compliance Officer
- PSPeter S. GreenleafConsultant
- MSMichael S. HearneChief Financial Officer
- RCRyan ColeChief Operating Officer
- JAJeffrey Allen BaileyIndependent Director
- CACraig A. JohnsonLead Independent Director
- KLKathy L. GoetzIndependent Director
- TSTina S. NovaIndependent Director
